Editing Psilocybin (section)

===Dosage===
{{See also|Psychedelic drug#Dosage|Psilocybin mushroom#Dosage}}

Psilocybin is used as a psychedelic at doses of 5 to 40{{nbsp}}mg [[oral administration|orally]].<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022">{{cite journal | vauthors = Liechti ME, Holze F | title = Dosing Psychedelics and MDMA | journal = Curr Top Behav Neurosci | volume = 56 | issue = | pages = 3–21 | date = 2022 | pmid = 34734392 | doi = 10.1007/7854_2021_270 | url = https://www.researchgate.net/profile/Matthias-Liechti/publication/355943062_Dosing_Psychedelics_and_MDMA/links/61896b7161f0987720707e29/Dosing-Psychedelics-and-MDMA.pdf}}</ref> Low doses are 5 to 10{{nbsp}}mg, an intermediate or "good effect" dose is 20{{nbsp}}mg, and high or [[ego dissolution|ego-dissolution]] doses are 30 to 40{{nbsp}}mg.<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022" /> Psilocybin's effects can be subjectively perceived at a dose as low as 3{{nbsp}}mg per 70{{nbsp}}kg body weight.<ref name="LiechtiHolze2022" /><ref name="HaslerGrimbergBenz2004">{{cite journal | vauthors = Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX | title = Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study | journal = Psychopharmacology | volume = 172 | issue = 2 | pages = 145–156 | date = March 2004 | pmid = 14615876 | doi = 10.1007/s00213-003-1640-6 | url = http://www.maps.org/research-archive/w3pb/2004/2004_Hasler_20465_2.pdf | url-status = live | access-date = April 10, 2019 | s2cid = 15263504 | archive-url = https://web.archive.org/web/20200418005513/https://maps.org/research-archive/w3pb/2004/2004_Hasler_20465_2.pdf | archive-date = April 18, 2020 }}</ref> [[Psychedelic microdosing|Microdosing]] involves the use of subthreshold psilocybin doses of less than 2.5{{nbsp}}mg.<ref name="HolzeSinghLiechti2024" /><ref name="LiechtiHolze2022" />

When psilocybin is used in the form of [[psilocybin-containing mushroom]]s, microdoses are 0.1{{nbsp}}g to 0.3{{nbsp}}g and psychedelic doses are 1.0{{nbsp}}g to 3.5–5.0{{nbsp}}g in the case of dried mushrooms.<ref name="KozlowskaNicholsWiatr2022">{{cite journal | vauthors = Kozlowska U, Nichols C, Wiatr K, Figiel M | title = From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders | journal = J Neurochem | volume = 162 | issue = 1 | pages = 89–108 | date = July 2022 | pmid = 34519052 | doi = 10.1111/jnc.15509 | url = | quote = One dosing method of psychedelics is the use of so called “microdoses”—very low concentrations of various psychedelics that do not reach the threshold of perceivable behavioral effects. This is usually 10% of active recreational doses (e.g., 10–15 µg of LSD, or 0.1–0.3 g of dry “magic mushrooms”) taken up to three times per week.}}</ref><ref name="vanAmsterdamOpperhuizenvandenBrink2011">{{cite journal | vauthors = van Amsterdam J, Opperhuizen A, van den Brink W | title = Harm potential of magic mushroom use: a review | journal = Regul Toxicol Pharmacol | volume = 59 | issue = 3 | pages = 423–429 | date = April 2011 | pmid = 21256914 | doi = 10.1016/j.yrtph.2011.01.006 | url = https://psilosybiini.info/paperit/Harm%20potential%20of%20magic%20mushroom%20use,%20A%20review%20(van%20Amsterdam%20et%20al.,%202011).pdf }}</ref><ref name="LoweToyangSteele2021" /> The preceding 1.0 to 5.0{{nbsp}}g range corresponds to psilocybin doses of about 10 to 50{{nbsp}}mg.<ref name="LoweToyangSteele2021" /> Psilocybin-containing mushrooms vary in their psilocybin and [[psilocin]] content, but are typically around 1% of the dried weight of the mushrooms (in terms of total or combined psilocybin and psilocin content).<ref name="vanAmsterdamOpperhuizenvandenBrink2011" /><ref name="PepeHesamidelaCerda2023">{{cite journal | vauthors = Pepe M, Hesami M, de la Cerda KA, Perreault ML, Hsiang T, Jones AM | title = A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond | journal = Biotechnol Adv | volume = 69 | issue = | pages = 108247 | date = December 2023 | pmid = 37659744 | doi = 10.1016/j.biotechadv.2023.108247 | url = }}</ref><ref name="TylšPáleníčekHoráček2014" /><ref name="LoweToyangSteele2021" /><ref name="Nichols2020">{{cite journal | vauthors = Nichols DE | title = Psilocybin: from ancient magic to modern medicine | journal = J Antibiot (Tokyo) | volume = 73 | issue = 10 | pages = 679–686 | date = October 2020 | pmid = 32398764 | doi = 10.1038/s41429-020-0311-8 | url = https://www.researchgate.net/publication/341321407 | quote = Total psilocybin and psilocin levels in species known to be used recreationally varied from 0.1% to nearly 2% by dry weight [8]. The medium oral dose of psilocybin is 4–8 mg, which elicits the same symptoms as the consumption of about 2 g of dried Psilocybe Mexicana [9].}}</ref><ref name="KurzbaumPáleníčekShrchaton2025">{{cite journal | vauthors = Kurzbaum E, Páleníček T, Shrchaton A, Azerrad S, Dekel Y | title = Exploring ''Psilocybe cubensis'' Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps | journal = Journal of Fungi | volume = 11 | issue = 2 | page = 99 | date = January 2025 | pmid = 39997393 | pmc = 11856550 | doi = 10.3390/jof11020099 | doi-access = free }}</ref><ref name="GoffSmithIslam2024">{{cite journal | vauthors = Goff R, Smith M, Islam S, Sisley S, Ferguson J, Kuzdzal S, Badal S, Kumar AB, Sreenivasan U, Schug KA | title = Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry | journal = Anal Chim Acta | volume = 1288 | issue = | pages = 342161 | date = February 2024 | pmid = 38220293 | doi = 10.1016/j.aca.2023.342161 | bibcode = 2024AcAC.128842161G | url = | quote = A method for clinical potency determination of psilocybin and psilocin in hallucinogenic mushroom species Psilocybe cubensis was developed using liquid chromatography with tandem mass spectrometry (LC-MS/MS). Five strains of dried, intact mushrooms were obtained and analyzed: Blue Meanie, Creeper, B-Plus, Texas Yellow, and Thai Cubensis. [...] From most to least potent, the study found that the average total psilocybin and psilocin concentrations for the Creeper, Blue Meanie, B+, Texas Yellow, and Thai Cubensis strains were 1.36, 1.221, 1.134, 1.103, and 0.879 % (w/w), respectively.}}</ref><ref name="GotvaldováBorovičkaHájková2022">{{cite journal | vauthors = Gotvaldová K, Borovička J, Hájková K, Cihlářová P, Rockefeller A, Kuchař M | title = Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids | journal = Int J Mol Sci | volume = 23 | issue = 22 | date = November 2022 | page = 14068 | pmid = 36430546 | pmc = 9693126 | doi = 10.3390/ijms232214068 | doi-access = free | url = }}</ref> Psilocin is about 1.4 times as potent as psilocybin because of the two compounds' difference in [[Molar mass|molecular weight]].<ref name="TylšPáleníčekHoráček2014" /><ref name="Hofmann1968">{{cite book | author = [[Albert Hofmann]] | chapter = Psychotomimetic Agents | pages = 169–235 | veditors = Burger A | title = Drugs Affecting the Central Nervous System | volume = 2 | date = 1968 | publisher = M. Dekker | location = New York | oclc = 245452885 | ol = OL13539506M | chapter-url = https://archive.org/details/drugsaffectingce0000edit/page/169/mode/1up | url = https://books.google.com/books?id=o_GMwgEACAAJ | quote = Psilocin is approximately 1.4 times as potent as psilocybin. This ratio is the same as that of the molecular weights of the two drugs.}}</ref><ref name="WolbachMinerIsbell1962">{{cite journal | vauthors = Wolbach AB, Miner EJ, Isbell H | title = Comparison of psilocin with psilocybin, mescaline and LSD-25 | journal = Psychopharmacologia | volume = 3 | issue = 3| pages = 219–223 | date = 1962 | pmid = 14007905 | doi = 10.1007/BF00412109 | url = | quote = Psilocin is approximately 1.4 times as potent as psilocybin. This ratio is the same as that of the molecular weights of the two drugs.}}</ref>